Chiovato L, Vitti P, Santini F, Lopez G, Mammoli C, Bassi P, Giusti L, Tonacchera M, Fenzi G, Pinchera A
Cattedra di Endocrinologia e Medicina Costituzionale, University of Pisa, Italy.
J Clin Endocrinol Metab. 1990 Jul;71(1):40-5. doi: 10.1210/jcem-71-1-40.
Autoantibodies blocking the TSH-dependent production of cAMP in thyroid cells (TSH-BAb) have been described in atrophic thyroiditis (AT; idiopathic myxedema) and in neonates with transient hypothyroidism, but their incidence in autoimmune thyroiditis in relation to thyroid status remains to be completely established. To this purpose TSH-BAb were evaluated in a group of 140 consecutive patients with autoimmune thyroiditis, which included 26 cases of AT and 114 subjects with goitrous Hashimoto's thyroiditis (HT); among the goitrous group 27 were euthyroid (HT-E), 32 had subclinical hypothyroidism (HT-SH), and 55 had clinical hypothyroidism (HT-H). TSH-BAb were measured in immunoglobulin G prepared by DEAE-Sephadex A-50 by determining their ability to inhibit TSH-dependent cAMP production in a differentiated strain of cultured rat thyroid cells (FRTL-5). Using this sensitive and reproducible method, TSH-BAb were detected in 12 of 26 (46%) patients with AT, in 1 of 27 (3.7%) subjects with HT-E, in 3 of 32 (9.4%) with HT-SH, and in 20 of 55 (36%) with HT-H. The prevalence of TSH-BAb was higher in AT vs. HT-H (P less than 0.001), HT-SH (P less than 0.001), or HT-E (P less than 0.001), and in HT-H vs. HT-SH (P less than 0.001) or HT-E (P less than 0.001). Mean TSH-BAb levels in AT were higher than those in HT-H (P less than 0.005) and HT-SH (P less than 0.025); the difference was not significant between HT-H and HT-SH. An inverse correlation was found between TSH-BAb levels and estimated goiter weight (P less than 0.005). The results of the present study indicate that 1) in autoimmune thyroiditis TSH-BAb are detectable almost exclusively in hypothyroid patients, their prevalence being higher in overt hypothyroidism than in subclinical thyroid failure; 2) the prevalence of TSH-BAb and their mean levels are higher in hypothyroid patients with AT than in those with HT; and 3) therefore, the presence of circulating TSH-BAb appears to be related to the development of hypothyroidism and thyroid atrophy.
在萎缩性甲状腺炎(AT;特发性黏液水肿)以及患有短暂性甲状腺功能减退症的新生儿中,已发现存在可阻断甲状腺细胞中促甲状腺激素(TSH)依赖性环磷酸腺苷(cAMP)生成的自身抗体(TSH-BAb),但其在自身免疫性甲状腺炎中与甲状腺状态相关的发生率仍有待完全明确。为此,对一组连续的140例自身免疫性甲状腺炎患者进行了TSH-BAb评估,其中包括26例AT患者和114例患有甲状腺肿性桥本甲状腺炎(HT)的受试者;在甲状腺肿组中,27例甲状腺功能正常(HT-E),32例有亚临床甲状腺功能减退(HT-SH),55例有临床甲状腺功能减退(HT-H)。通过测定免疫球蛋白G抑制培养的大鼠甲状腺细胞分化株(FRTL-5)中TSH依赖性cAMP生成的能力,来检测经DEAE-葡聚糖A-50制备的免疫球蛋白G中的TSH-BAb。使用这种灵敏且可重复的方法,在26例AT患者中有12例(46%)检测到TSH-BAb,在27例HT-E受试者中有1例(3.7%),在32例HT-SH患者中有3例(9.4%),在55例HT-H患者中有20例(36%)检测到TSH-BAb。AT患者中TSH-BAb的患病率高于HT-H(P<0.001)、HT-SH(P<0.001)或HT-E(P<0.001),HT-H患者中TSH-BAb的患病率高于HT-SH(P<0.001)或HT-E(P<0.001)。AT患者中TSH-BAb的平均水平高于HT-H(P<0.005)和HT-SH(P<0.025);HT-H和HT-SH之间差异不显著。发现TSH-BAb水平与估计的甲状腺肿重量呈负相关(P<0.005)。本研究结果表明:1)在自身免疫性甲状腺炎中,TSH-BAb几乎仅在甲状腺功能减退患者中可检测到,其在显性甲状腺功能减退中的患病率高于亚临床甲状腺功能减退;2)AT甲状腺功能减退患者中TSH-BAb的患病率及其平均水平高于HT甲状腺功能减退患者;3)因此,循环中TSH-BAb的存在似乎与甲状腺功能减退和甲状腺萎缩的发生有关。